secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-PATH HOLDINGS, INC. (BPTH)
CIK:        0001133818
Form:       8-K
Filed at:   2023-11-15T23:59:59+00:00
Accession:  0001558370-23-019085
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Path Q3 net loss $3.2M; positive prexigebersen AML Phase 2 data
-------------------------------------------------------------------

- Net loss of $3.2M ($0.32/sh) vs $3.5M ($0.49/sh) in Q3 2022, improvement from lower expenses and warrant income.
- Cash $2.4M as of Sep 30, 2023, down from $10.4M at Dec 31, 2022; net cash used in ops $9.7M in nine months.
- Positive Phase 2 interim data for prexigebersen in AML; results exceed outcomes of decitabine/venetoclax alone.
- R&D expense $2.3M (down from $2.4M), G&A $1.0M (down from $1.2M) year-over-year.
- KOL event in October with MD Anderson and Georgia Cancer Center experts discussing prexigebersen potential.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133818/000155837023019085/0001558370-23-019085-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133818/000155837023019085/bpth-20231115x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-019085

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer